July 08, 2011 09:02 ET

eResearch Issues Initiating Report on Microbix Biosystems Inc.

TORONTO, ONTARIO--(Marketwire - July 8, 2011) - Microbix Biosystems Inc. (TSX:MBX) is a biotechnology company that is focused on leveraging its Core Base Business unit that has commercialized over 60 products in the virology and cell culture technologies in order to finance its potentially more-lucrative large-market pipeline of products.

Microbix is on the threshold of moving from the potential phase into commercial realization. No longer just a development biotech company, Microbix expects to have exciting opportunities commercially ready over the next 18-24 months, which would put the Company on a high-growth trajectory.

With strong growth opportunities in large markets, Microbix is ready to make the break-through in realizing on its long-term vision. Our 12-month Target Price of $1.15 per share reflects our expectations that the Company will achieve its strategic objectives.

This Press Release was prepared by eResearch and was not vetted by Microbix Biosystems Inc. Further, the Recommendation and Target Prices contained in this Press Release and in the Initiating Report are strictly those of eResearch and, due to securities laws, are not endorsed by Microbix Biosystems Inc.

eResearch is a primary source for professional investment research, focused primarily on small- and mid-cap companies. Our research and analysis is of institutional quality, and has the potential for reaching millions of global investors through our extensive electronic distribution network.

Microbix Biosystems Inc. paid eResearch a fee to conduct research on the Company, on an Annual Continuous Coverage basis.

For FREE access to all eResearch reports and articles, go to

Contact Information